AI IN DRUG DISCOVERY USA

Kongressthemen
Artificial Intelligence (AI) is leading technological advancements in the pharmaceutical sector, poised to transform pre-clinical drug discovery by reducing costs by up to 40% and creating a market valued at up to $50 billion in the next decade. This transformative period is upon us, and the AI in Drug Discovery conference offers a unique opportunity to hear directly from experts and gain strategies to enhance your operations.

Zielpublikum
The conference is ideal for companies aiming to expedite the delivery of therapeutics to patients, thereby extending healthy longevity. Attendees will learn how to build an AI ecosystem by combining internal and external resources

Kongressorganizer (PCO)
SAE Media Group

Anmerkungen
URL:
Brochure: https://go.evvnt.com/2449688-2?pid=4832

Speakers: DR BINO JOHN - Director, Computational Biology, Cancer Immunology and Immune Modulation, Boehringer Ingelheim, DR DMITRIY PODOLSKIY - Associate Director, Astellas Pharma, and more

https://go.evvnt.com/2449688-0?pid=4832

Herr Elliot Karmel